Tandem Diabetes Care Q1 2024 Adj EPS $(0.65) Beats $(0.76) Estimate, Sales $192.80M Beat $174.02M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tandem Diabetes Care (NASDAQ:TNDM) reported Q1 2024 adjusted EPS of $(0.65), surpassing the $(0.76) estimate, with sales of $192.80M exceeding the $174.02M forecast. This represents a 13.82% increase in sales compared to the same period last year.
May 02, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tandem Diabetes Care reported a Q1 2024 adjusted EPS of $(0.65) and sales of $192.80M, both surpassing analyst estimates and showing significant year-over-year growth.
Tandem Diabetes Care's Q1 2024 financial results exceeded analyst expectations in both EPS and sales, indicating strong financial performance and potential for positive market reaction. The significant year-over-year sales growth further underscores the company's positive trajectory, likely leading to increased investor confidence and a potential uptick in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100